Intensity Therapeutics (INTS) Current Leases (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Current Leases came in at $32000.0 in Q1 2026, up 10.34% YoY from $29000.0 in Q1 2025, and up 3.23% on a QoQ basis from $31000.0 in Q4 2025.
Intensity Therapeutics (INTS) Current Leases (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Current Leases data on file, last reported at $32000.0 in Q1 2026.
- Quarterly Current Leases rose 10.34% year-over-year to $32000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32000.0 (up 10.34% YoY) and the FY2025 annual result came in at $31000.0, up 10.71% from the prior year.
- Current Leases advanced to $32000.0 in Q1 2026, from $31000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $143000.0 in Q4 2022 to a low of $10556.0 in Q3 2023.
- A 5-year average of $36296.3 and a median of $28500.0 in 2024 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2023 — Current Leases slumped 86.01% — and 2024, when it soared 165.25%.
- Tracing INTS's Current Leases over 5 years: stood at $143000.0 in 2022, then tumbled by 86.01% to $20000.0 in 2023, then jumped by 40.0% to $28000.0 in 2024, then rose by 10.71% to $31000.0 in 2025, then advanced by 3.23% to $32000.0 in 2026.
- The last three Current Leases figures came in at $32000.0 (Q1 2026), $31000.0 (Q4 2025), and $31000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | - |
| 10 | Intensity Therapeutics | 12.80 Mn | 12.80 Mn | - | 33,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33,000.00 |
| Mar 31, 2026 | 32,000.00 |
| Dec 31, 2025 | 31,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | 29,000.00 |
| Dec 31, 2024 | 28,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 27,000.00 |
| Mar 31, 2024 | 26,000.00 |
| Dec 31, 2023 | 20,000.00 |
| Sep 30, 2023 | 10,556.00 |
| Dec 31, 2022 | 143,000.00 |